BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call

Core Viewpoint - BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products to combat serious infections caused by multidrug-resistant bacteria, with a financial results announcement scheduled for March 18, 2026 [1][2]. Group 1: Financial Results and Conference Call - BioVersys will publish its Full Year 2025 financial results on March 18, 2026, with a press release issued at 7:00 AM CET / 2:00 AM ET [2]. - Following the financial results release, a conference call and webcast will take place on the same day at 2:00 PM CET / 9:00 AM ET, where management will review the results and provide a business update [2]. Group 2: Company Overview - BioVersys AG specializes in identifying, developing, and commercializing antibacterial products targeting life-threatening infections from multidrug-resistant bacteria [4]. - The company utilizes two internal technology platforms, TRIC and Ansamycin Chemistry, to develop candidates that can overcome resistance mechanisms and address unmet medical needs in antimicrobial treatments [4]. - BioVersys's advanced R&D programs include a Phase 3 study for nosocomial infections caused by Acinetobacter baumannii (BV100) and a Phase 2b study for tuberculosis (alpibectir) in collaboration with GlaxoSmithKline and the University of Lille [4].